Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director departure Appointed director
|
Enveric Biosciences, Inc. (AMRH)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/11/2023 |
8-K
| Quarterly results |
10/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/27/2023 |
8-K
| Quarterly results |
08/21/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/14/2023 |
8-K
| Quarterly results |
08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/24/2023 |
8-K
| Quarterly results |
07/17/2023 |
8-K
| Quarterly results |
06/08/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
06/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
06/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/24/2023 |
8-K
| Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen... |
05/24/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/19/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/18/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/19/2023 |
D/A
| Form D/A - Notice of Exempt Offering of Securities: [Amend] |
04/03/2023 |
8-K
| Quarterly results |
03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/23/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
03/21/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
03/14/2023 |
4
| Coveney Kevin Michael (CFO) has filed a Form 4 on Enveric Biosciences, Inc.
Txns:
| Granted 26,500 shares
@ $0 |
|
03/14/2023 |
3
| Coveney Kevin Michael (CFO) has filed a Form 3 on Enveric Biosciences, Inc. |
03/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
02/28/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
02/23/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
02/14/2023 |
SC 13G
| AdvisorShares Trust reports a 5.6% stake in Enveric Biosciences, Inc. |
02/08/2023 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 9.4% stake in Enveric Biosciences, Inc. |
02/07/2023 |
SC 13G
| Hudson Bay Capital Management LP reports a 5% stake in Enveric Biosciences, Inc. |
02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/27/2023 |
4
| Facchini Peter J. (Chief Innovation Officer) has filed a Form 4 on Enveric Biosciences, Inc.
Txns:
| Granted 17,000 shares
@ $0 |
|
01/27/2023 |
4
| Hagel Jillian Marie (Vice President of Innovation) has filed a Form 4 on Enveric Biosciences, Inc.
Txns:
| Granted 12,000 shares
@ $0 |
|
01/27/2023 |
4
| Kanubaddi Avani (President and COO) has filed a Form 4 on Enveric Biosciences, Inc.
Txns:
| Granted 10,000 shares
@ $0 |
|
01/27/2023 |
4
| Tucker Joseph Edward (CEO) has filed a Form 4 on Enveric Biosciences, Inc.
Txns:
| Granted 44,000 shares
@ $0 |
|
|
|
|